I can start and then turn to Deputy Minister Lucas.
Quite frankly, the answer is that we're not comparing apples to oranges in many cases. For example, AstraZeneca can be produced in multiple sites across the world. When Health Canada does an approval, it's looking at not just the efficacy and the safety of the vaccine itself, but also the manufacturing data that goes along with where the doses destined for Canada will be produced, along with data on the individual lots that Canada is purchasing.
It seems that we're all approving the same vaccine, but in fact a vaccine produced in India versus a vaccine produced in the U.K. versus a vaccine produced in the U.S. may all have different manufacturing data that needs to be analyzed through the lens of safety.
I will turn to Deputy Minister Lucas to fill in a few more details.